Skip to main content
Jafron Biomedical Co.,Ltd. logo

Jafron Biomedical Co.,Ltd. — Investor Relations & Filings

Ticker · 300529 ISIN · CNE100002995 Shenzhen Stock Exchange Manufacturing
Open in API
Filings indexed 1,842 across all filing types
Latest filing 2021-06-20 Capital/Financing Update
Country CN China
Listing Shenzhen Stock Exchange 300529

About Jafron Biomedical Co.,Ltd.

https://www.jafron.com

Jafron Biomedical Co.,Ltd. specializes in the research, development, and manufacturing of biomaterials and equipment for blood purification. The company is a primary provider of hemoperfusion technology, focusing on the production of adsorbent cartridges designed to remove specific toxins and inflammatory mediators from the bloodstream. Its core product portfolio includes the HA series of hemoperfusion cartridges, which are applied in clinical settings for end-stage renal disease, acute poisoning, critical care, and liver failure. Beyond consumables, the company develops blood purification machines and integrated treatment systems. These solutions target clinical applications in nephrology, intensive care, and hepatology. By leveraging advanced resin adsorption technology, the company provides specialized extracorporeal blood treatment options aimed at improving patient outcomes in complex medical conditions.

Recent filings

Filing Released Lang Actions
向不特定对象发行可转换公司债券发行公告
Capital/Financing Update Classification · 100% confidence The document is a detailed announcement regarding the issuance of convertible corporate bonds by 健帆生物科技集团股份有限公司. It includes extensive information about the bond issuance process, terms, conditions, subscription details, pricing, redemption, and other related financial and regulatory information. The document references regulatory approvals, issuance dates, subscription procedures, and underwriting details. It is not a financial report like an annual or quarterly report, nor is it a transcript, audit report, or management report. It is a formal announcement of a capital raising activity through convertible bonds, which fits the category of Capital/Financing Update (CAP). The document length and detail confirm it is the announcement itself, not a brief notice or a report publication announcement.
2021-06-20 Chinese
中航证券有限公司关于公司创业板向不特定对象发行可转换公司债券之发行保荐书
Capital/Financing Update Classification · 95% confidence The document is a detailed sponsorship letter (保荐书) from a securities company regarding the issuance of convertible bonds by a listed company. It includes extensive information about the issuer, the securities issuance, legal and regulatory compliance, financial data, and internal review procedures. The document references Chinese securities laws, regulatory requirements, and audit reports. It is not a simple announcement but a comprehensive regulatory filing related to a capital market transaction (issuance of convertible bonds). This fits the category of Capital/Financing Update (CAP), which covers updates on company fundraising and financing activities. The document length and detail confirm it is not a mere announcement or a short notice. Therefore, the classification is CAP with high confidence.
2021-06-20 Chinese
独立董事关于公司第四届董事会第十八次会议相关事项的独立意见
Capital/Financing Update Classification · 95% confidence The document is an independent opinion statement from independent directors regarding specific proposals related to the issuance of convertible bonds by the company. It references compliance with regulatory guidelines and company rules, and provides formal approval opinions on bond issuance plans, listing, and fund management. The content is focused on governance and regulatory compliance related to financing activities, but it is not a full financial report or audit. The document length is short (924 characters) and it is a formal opinion rather than a report or announcement of a report. This fits best under Capital/Financing Update (CAP) as it relates to the company's financing activities and bond issuance plans.
2021-06-20 Chinese
第四届监事会第十八次会议决议公告
Capital/Financing Update Classification · 95% confidence The document is a formal announcement of resolutions passed at the 18th meeting of the 4th Supervisory Board of the company. It details decisions related to the issuance of convertible bonds, including issuance scale, interest rates, redemption terms, issuance methods, and related authorizations. The document is an official meeting resolution announcement rather than a financial report or earnings release. It does not contain financial statements or detailed financial analysis but focuses on capital raising activities and related approvals. Therefore, it fits best under the category of Capital/Financing Update (CAP). The document length is 3290 characters, which is consistent with an announcement rather than a full report. Hence, the classification is CAP with high confidence.
2021-06-20 Chinese
创业板向不特定对象发行可转换公司债券募集说明书摘要
Capital/Financing Update Classification · 95% confidence The document is a detailed prospectus summary for a convertible bond issuance by Jafron Biomedical Co., Ltd. It includes extensive information about the bond issuance terms, company background, financial data, risk factors, credit ratings, and regulatory approvals. The text references the China Securities Regulatory Commission's approval and contains detailed financial and operational disclosures related to the bond offering. This type of document is a formal offering prospectus or a detailed capital/financing update related to a fundraising event. It is not an annual report, earnings release, or management discussion, nor is it a simple announcement or certification. Given the detailed nature of the bond issuance information and the fundraising context, the document best fits the category of Capital/Financing Update (CAP).
2021-06-20 Chinese
创业板向不特定对象发行可转换公司债券募集说明书
Capital/Financing Update Classification · 95% confidence The document is titled as a "募集说明书" which translates to "Offering Circular" or "Prospectus" for a convertible bond issuance by Jafron Biomedical Co., Ltd. It contains detailed information about the bond issuance, including credit ratings, risk factors, company background, financial data, dividend policies, and regulatory compliance. The document is lengthy (15,000 characters) and includes comprehensive financial and operational details related to the capital raising activity. This matches the definition of a Capital/Financing Update (CAP), which covers updates on company fundraising and financing activities. It is not an annual report, earnings release, or other report types, but specifically a detailed disclosure related to a convertible bond issuance. Therefore, the correct classification is CAP with high confidence.
2021-06-20 Chinese

Browse filings by year

11 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.